Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH

Anti-recurrence Treatment of Postresection on Hepatocellular Carcinoma Patients With Microvascular Invasion Presence and Over-expression of Aspartate Beta-hydroxylase: A Randomized Controlled Study

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02587884

Enrollment

180

Registered

2015-10-27

Start date

Unknown

Completion date

2017-12-31

Last updated

2016-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

Recurrence, Microvascular Invasion, Aspartate beta-hydroxylase

Brief summary

The aim of this study is to explore the effect of Transarterial Chemoembolization (TACE) on the prognosis of patients with microvascular invasion presence(MVI) and overexpression of Aspartate-β-hydroxylase(ASPH).

Interventions

PROCEDURETACE

Patients will treated by TACE in 4 or 8 weeks after operation.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Via clinical diagnosis and confirm it is primary liver cancer 2. Pathological evidence of HCC 3. Confirm presence of MVI and over-expression of ASPH after opreation 4. Within Milan criteria 5. Estimate tumor can gain treatment of curing operation 6. No evidence for extrahepatic metestasis 7. liver function ：Child-Pugh A/B

Exclusion criteria

1. Reject to attend 2. Impossible to come to our hospital for physical examination regularly 3. Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction 4. Female with pregnancy or during the lactation period

Design outcomes

Primary

Measure	Time frame
Overall Survival	3 years

Secondary

Measure	Time frame
Time to recurrence	3 years

Countries

China

Contacts

Primary ContactWang Kui, MD

wangkuiykl@163.com86-021-81875242

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026